In Vivo Evaluation of Pam2Cys‐Modified Cancer‐Testis Antigens as Potential Self‐Adjuvanting Cancer Vaccines
Fuente:
Wiley Open Access
Salvato in:
| Autori principali: | , , , , , , , , |
|---|---|
| Natura: | Artículo Open Access |
| Pubblicazione: |
Wiley
2025
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1867004408597839873 |
|---|---|
| author | Salwa Aljohani Alex G. Edmonds Valeria Castelletto Jani Seitsonen Ian W. Hamley Peter Symonds Victoria A. Brentville Lindy G. Durrant Nicholas J. Mitchell |
| author_facet | Salwa Aljohani Alex G. Edmonds Valeria Castelletto Jani Seitsonen Ian W. Hamley Peter Symonds Victoria A. Brentville Lindy G. Durrant Nicholas J. Mitchell Salwa Aljohani Alex G. Edmonds Valeria Castelletto Jani Seitsonen Ian W. Hamley Peter Symonds Victoria A. Brentville Lindy G. Durrant Nicholas J. Mitchell |
| collection | Wiley Open Access |
| contents | In Vivo Evaluation of Pam2Cys‐Modified Cancer‐Testis Antigens as Potential Self‐Adjuvanting Cancer Vaccines Salwa Aljohani Alex G. Edmonds Valeria Castelletto Jani Seitsonen Ian W. Hamley Peter Symonds Victoria A. Brentville Lindy G. Durrant Nicholas J. Mitchell Journal of Peptide Science ABSTRACTPeptide‐based vaccines, formulated with an appropriate adjuvant, offer a versatile platform for targeted cancer immunotherapy. While adjuvants are usually coadministered for nucleic acid and protein vaccines, synthetic peptide antigens afford a more effective opportunity to covalently and regioselectively graft immunostimulatory motifs directly onto the antigen scaffold to yield self‐adjuvanting vaccines. Herein, we explore the synthesis of two tissue‐restricted cancer‐testis antigens (CTAs); New York oesophageal cell carcinoma 1 (NY‐ESO‐1) and B melanoma antigen 4 (BAGE4), both carrying the toll‐like receptor (TLR) agonist, Pam2Cys. These constructs were evaluated in vivo along with a lipid nanoparticle (LNP) preparation of the underexplored BAGE4 melanoma antigen. 10.1002/psc.70022 http://creativecommons.org/licenses/by/4.0/ |
| doi_str_mv | 10.1002/psc.70022 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_psc_70022 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by/4.0/ |
| publishDate | 2025 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | In Vivo Evaluation of Pam2Cys‐Modified Cancer‐Testis Antigens as Potential Self‐Adjuvanting Cancer Vaccines Salwa Aljohani Alex G. Edmonds Valeria Castelletto Jani Seitsonen Ian W. Hamley Peter Symonds Victoria A. Brentville Lindy G. Durrant Nicholas J. Mitchell Journal of Peptide Science In Vivo Evaluation of Pam2Cys‐Modified Cancer‐Testis Antigens as Potential Self‐Adjuvanting Cancer Vaccines Salwa Aljohani Alex G. Edmonds Valeria Castelletto Jani Seitsonen Ian W. Hamley Peter Symonds Victoria A. Brentville Lindy G. Durrant Nicholas J. Mitchell Journal of Peptide Science ABSTRACTPeptide‐based vaccines, formulated with an appropriate adjuvant, offer a versatile platform for targeted cancer immunotherapy. While adjuvants are usually coadministered for nucleic acid and protein vaccines, synthetic peptide antigens afford a more effective opportunity to covalently and regioselectively graft immunostimulatory motifs directly onto the antigen scaffold to yield self‐adjuvanting vaccines. Herein, we explore the synthesis of two tissue‐restricted cancer‐testis antigens (CTAs); New York oesophageal cell carcinoma 1 (NY‐ESO‐1) and B melanoma antigen 4 (BAGE4), both carrying the toll‐like receptor (TLR) agonist, Pam2Cys. These constructs were evaluated in vivo along with a lipid nanoparticle (LNP) preparation of the underexplored BAGE4 melanoma antigen. 10.1002/psc.70022 http://creativecommons.org/licenses/by/4.0/ |
| title | In Vivo Evaluation of Pam2Cys‐Modified Cancer‐Testis Antigens as Potential Self‐Adjuvanting Cancer Vaccines |
| topic | Journal of Peptide Science |
| url | https://onlinelibrary.wiley.com/doi/10.1002/psc.70022 |